Many next-generation sequencing applications use the Polymerase Chain Reaction, or PCR, for DNA amplification. This video presents best practices to minimize the potential for PCR contamination in your experiment.
Recorded Webinar (July 2019) | TruSight Oncology 500 is a next-generation sequencing tumor profiling assay that analyzes 523 genes for cancer-related biomarkers and supports the identification of DNA and RNA variants implicated in various tumor types, including measuring key immunotherapy biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI). This webinar focuses on the DNA analysis and is targeted at new users of the TruSight Oncology 500 workflow. We will go over the following topics: overview of the TruSight Oncology 500 DNA analysis workflow, how to assess biomarker (TMB and MSI) results, and options for data analysis and variant interpretation